IPF Weekly Update - AIとIPFと癒しの音楽

ChatGPTを活用して業務のAI化を進めています。プロンプトエンジニアリングの専門家です！と、名乗れるレベルではありませんが、かなり色々使いこなしてきています。この１年、病気で失われた能力は、別な能力を発達させる、進化することで生き残っていこうと思います。

<><><>

23/06/24

[HTML] Integrative multi-omics analysis reveals novel idiopathic pulmonary fibrosis endotypes associated with disease progression

P Ruan, JL Todd, H Zhao, Y Liu, R Vinisko, JF Soellner… - Respiratory Research, 2023

… Idiopathic pulmonary fibrosis (IPF) is characterized by the accumulation of extracellular matrix in the pulmonary interstitium and progressive functional decline. We hypothesized that integration of multi-omics data would identify clinically …

統合的なマルチオミクス解析により、疾患の進行に関連する新たな特発性肺線維症のエンドタイプが明らかに

Idiopathic Pulmonary Fibrosis: 8 Years On After Nintedanib and Pirfenidone Approval—What Is on the Horizon?

G Castelli, E Cocconcelli, N Bernardinello, E Balestro… - Current Pulmonology …, 2023

… The approval of nintedanib and pirfenidone has changed the treatment landscape of idiopathic pulmonary fibrosis (IPF); however, both drugs only slow disease progression and are burdened by tolerability issues. We summarize the …

特発性肺線維症: ニンテダニブとピルフェニドンの承認から 8 年 - 今後の展望は?

Epidemiology and comorbidities in idiopathic pulmonary fibrosis: a nationwide cohort study

L Jang Ho, P Hyung Jun, K Seonok - 2023

… Epidemiology and comorbidities in idiopathicpulmonary fibrosis: a nationwide cohort study … Abstract: Idiopathic pulmonary fibrosis(IPF) is frequently accompanied by comorbidities, with the … impact of comorbidities in IPF patients …

特発性肺線維症の疫学と併存症：全国的なコホート研究

Local administration of liposomal-based Plekhf1 gene therapy attenuates pulmonary fibrosis by modulating macrophage polarization

L Yan, C Hou, J Liu, Y Wang, C Zeng, J Yu, T Zhou… - Science China Life …, 2023

… Idiopathic pulmonary fibrosis (IPF) is a fatal interstitial lung disease with limited therapeutic options. Macrophages, particularly … a viable therapeutic strategy for IPF. Herein, we report a potential nanomedicinebased gene therapy for IPF by …

リポソームベースのPlekhf1遺伝子治療の局所投与は、マクロファージの極性化を調節することにより肺線維症を軽減する

Chronic Respiratory Disease: COPD, IPF

RA Incalzi, FL Fimognari - Optimizing Pharmacotherapy in Older Patients: An …, 2023

… Idiopathic pulmonary fibrosis (IPF), the most common (about 50% of all idiopathicILDs), is characterized by histopathologic and high-… NSIP, the most frequent idiopathic ILD after IPF, is currently treated with corticosteroids (starting from 0.5–1 …

慢性呼吸器疾患: COPD、IPF

23/06/22

[PDF] Idiopathic pulmonary fibrosis: current diagnosis and treatment

A Franco, R Adib - J Bras Pneumol, 2023

… Idiopathic pulmonary fibrosis (IPF) is a devastating chronic lung disease without a clear recognizable cause. IPF has been at the forefront … influencing the management of fibrotic interstitial lung diseases other than IPFitself. Clinical …

特発性肺線維症：現在の診断と治療

AH Hansen, HW Breisnes, TS Prior, O Hilberg… - Clinical Biochemistry, 2023

… Idiopathic pulmonary fibrosis (IPF) is a complex chronic disease of unknown cause with a high mortality rate and significant impact on patients’ quality of life.[1], [2], [3] The rate of disease progression is hard to predict due to a high degree of …

血清学的に評価された細胞フィブロネクチン分解のネオエピトープバイオマーカーは肺線維症に関連している

hucMSCs treatment prevents pulmonary fibrosis by reducing circANKRD42-YAP1-mediated mechanical stiffness

H Zhang, Q Zhu, Y Ji, M Wang, Q Zhang, W Liu, R Li… - Aging

… Idiopathic pulmonary fibrosis (IPF) is a fibrosing interstitial pneumonia of unknown cause. The most typical characteristic of IPF is gradual … This study aims to identify a novel treatment approach for IPF and explore mechanism of mechanical …

hucMSCs 治療は、circANKRD42-YAP1 媒介の機械的剛性を低下させることにより肺線維症を予防します

23/06/20

Polygenic risk of idiopathic pulmonary fibrosis and COVID-19 severity (preprint)

B Guillen-Guio, I Marcelino-Rodriguez… - 2023

… genetic overlap between IPF and severe COVID-19 that is dependent on age and sex and adds further support that the pathogenesis of both IPF and severe COVID-19 share underlying biological mechanisms. This could imply that individuals with a …

特発性肺線維症の多遺伝子性リスクと新型コロナウイルス感染症の重症度（プレプリント）

Novel Immune Responses in Lung Injury and Fibrosis

Y me Yoon - 2023

… Herein, we revealed a common adaptive immune landscape in LLNs of all ILD patients including idiopathic pulmonary fibrosis (IPF), characterized by highly activated germinal centers and antigen-activated T cells. T regulatory cells (Tregs) …

肺損傷および線維症における新たな免疫反応

M He, J Zhou, T Yang, X Li, R Wang - 2023

… treatment of idiopathic pulmonary fibrosis(IPF), … IPF, confirming the most of the corresponding label information is relatively safe. However, some unexpected risk signals should be taken seriously, and further research is needed to manage the …

米国食品医薬品局有害事象報告システムと VigiAccess データベースに基づく抗線維化薬関連の有害事象の実世界研究

H Zhang, D Jiang, L Zhu, G Zhou, B Xie, Y Cui… - Frontiers in Immunology

… (BALF) of 62 sarcoidosis patients, 66 idiopathic pulmonary fibrosis (IPF) patients and 41 healthy … IPF patients or healthy donors. To the contrary, a lower frequency of Tregs and a greater proportion of Th17.1 cells was found in BALF of sarcoidosis …

サルコイドーシス患者の末梢血およびBALFにおける制御性T細胞およびTh17.1細胞の不均衡な分布：疾患活動性および線維性X線写真表現型に関連する

Insights on the mechanism of bleomycin to induce lung injury and associated in vivo models: A review

BL Ayilya, A Balde, M Ramya, S Benjakul, SK Kim… - International …, 2023

… Acute lung injury leads to the development of chronic conditions such as idiopathicpulmonary fibrosis (IPF), chronic obstructive pulmonary disease (COPD), asthma as well as alveolar sarcoma. Various investigations are being performed …